CONNECTIVINA PLUS ® - Hyaluronic acid + Silver sulfadiazine

CONNETTIVINA PLUS ® is a drug based on hyaluronic acid + silver sulfadiazine

THERAPEUTIC GROUP: Antibiotics and chemotherapy for topical use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions CONNECTIVINA PLUS ® - Hyaluronic acid + Silver sulfadiazine

CONNETTIVINA PLUS ® is a medicine indicated for the local treatment of sores, burns, ulcers and dermatological lesions susceptible to bacterial infections.

Mechanism of action CONNETTIVINA PLUS ® - Hyaluronic acid + Silver sulfadiazine

CONNETTIVINA PLUS ® is a medicinal specialty particularly used in dermatology and surgery especially in the prophylaxis of bacterial infections of traumatic lesions, burns and skin sores.

Its preventive-therapeutic action is due to the presence of the two active ingredients:

Hyaluronic acid, mucopolysaccharide particularly expressed in the connective tissue and in particular in the dermis, fundamental in structuring the matrix by providing an anatomical, functional and nutritional support to the overlying cellular elements. The correct intake of this substance has proved to be fundamental in speeding up the healing time, favoring both the reconstitution of the dermis and the re-epithelialization of the lesion;

Sulfadiazine Argentica, an active ingredient belonging to the family of sulfonamide antibiotics capable of inhibiting bacterial replication, thanks to the ability of the sulphadiazine radical to compete with the paraminobenzoic enzyme and to interfere with the bacterial synthesis of folic acid, and thanks to the presence of the ion Silver, useful in carrying out a broad-spectrum bactericidal action, molecularly not yet characterized.

The various studies have underlined the preventive capacities of CONNETTIVINA PLUS ® especially with respect to pathogens such as Pseudomonas aeuriginosa and Enterobacter piogenes, largely responsible for infections found during wounds and burns.

Studies carried out and clinical efficacy

ARGENTIC SULPHADIAZINE IN DIABETIC INJURIES

An all-Italian work that demonstrates how the topical use of hyaluronic acid and silver sulfadiazine can be effective and safe in the prophylaxis of bacterial infections of diabetic lesions, especially when sustained by microorganisms normally resistant to common antibiotic therapy.

HYALURONIC ACID AND ARGENTIC SULPHADIAZINE IN SURGERY

Experimental study conducted on small laboratory animals which demonstrated how the use of creams based on hyaluronic acid and silver sulfadiazine can improve wound healing after laser surgical therapy, significantly reducing infectious complications.

THE USE OF SULFADIAZINA ARGENTICA AND HYALURONIC ACID IN BURNS

Clinical trial demonstrating that the association of silver sulfadiazine and hyaluronic acid may be more effective than silvery sulfadiazine alone in improving clinical course and prognosis of patients with second-degree burns.

Method of use and dosage

CONNECTIVINA PLUS ®

Impregnated gauze 10x10, 10x20, 20x30;

200 mg cream of hyaluronic acid sodium salt + silver sulfadiazine 1 g per 100 g of product.

We recommend applying a correct amount of cream or medicated gauze over the lesion, at least twice a day.

The use of CONNETTIVINA PLUS ® must be prolonged until the wound is completely healed.

In order to optimize therapeutic efficacy it is recommended to thoroughly cleanse the area before and after each application using sterile disposable gloves.

Warnings CONNETTIVINA PLUS ® - Hyaluronic acid + Silver sulfadiazine

Although the systemic absorption of the active ingredients contained in CONNETTIVINA PLUS ® is insignificant, it is advisable that the drug be used with caution in patients suffering from serious renal pathologies rather than from hypersensitivity to the active ingredient or to one of its excipients.

It is also recommended to avoid direct exposure to ultraviolet rays during therapy with CONNETTIVINA PLUS ®.

PREGNANCY AND BREASTFEEDING

Given the absence of studies capable of totally characterizing the safety profile of Sulfadiazine Argentica for fetal health, it is recommended to avoid the use of CONNETTIVINA PLUS ® during pregnancy and in the subsequent period of lactation unless it is indispensable.

Interactions

The patient in therapy with CONNETTIVINA PLUS ® should pay particular attention to the simultaneous application on site of creams, ointments or solutions based on proteolytic enzymes.

Contraindications CONNETTIVINA PLUS ® - Hyaluronic acid + Silver sulfadiazine

The use of CONNETTIVINA PLUS ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients.

Undesirable effects - Side effects

Although the use of CONNETTIVINA PLUS ® is generally safe and well tolerated, sometimes, especially after the continuous and extended application of the medicine, symptoms such as pain and burning in the seat and local allergic reactions may occur.